Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Onyx Scientific Reports Growth in Chemistry Services | Contract Pharma
Breaking News

Onyx Scientific Reports Growth in Chemistry Services

Solid formulation revenues up 45%

Onyx Scientific reported a 45% growth in its solid formulation-related revenues this year, driven by early stage drug development projects. The company’s alliance with Molecular Profiles has also contributed to growth, with increased activity in the biotechnology and early stage clinical sector.
 
Denise Bowser, commercial director at Onyx Scientific, said, “Over the past few years, we have proudly become a real specialist in solid-state chemistry focused on providing detailed investigation to cut lead times for clients and ensure processes are scalable. As many drugs are formulated in solid dosage form, the need to understand, control and characterize the individual forms of a substance, in particular the polymorphic form is vital. This is why we feel we have seen such an increased demand.”
 
Onyx Scientific, a contract research and manufacturing organization, has MHRA and FDA facilities in the UK and India, and provides medicinal chemistry and preclinical through Phase I-III, scaling up to large scale commercial API production.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters